NCT04053907 (INDIE-1b) is a NA clinical trial of Community Case Management in Malaria, sponsored by London School of Hygiene and Tropical Medicine.

Who is sponsoring NCT04053907?

NCT04053907 is sponsored by London School of Hygiene and Tropical Medicine.

What drugs are being tested in NCT04053907?

Interventions in NCT04053907: Community Case Management, Weekly fever screening and treatment, Monthly malaria screening, MDA.

Is NCT04053907 still recruiting?

NCT04053907 is currently status unknown. Last updated 31 March 2022.

Last reviewed 2022-03-31 · How we verify

NCT04053907: INDIE-1b

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

P. Falciparum Infection Dynamics and Transmission to Inform Elimination

Status unknown NA Last updated 31 March 2022

What this trial tests

NA trial testing Community Case Management in Malaria in 4,000 participants. Status unknown.

Timeline

15 August 2019

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	London School of Hygiene and Tropical Medicine
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	4,000
Start date	15 August 2019
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	1 location across The Gambia

Drugs / interventions tested

Community Case Management
Weekly fever screening and treatment
Monthly malaria screening
MDA — full drug profile →

Conditions studied

Malaria — all drugs for Malaria →

Sponsor

London School of Hygiene and Tropical Medicine

Who can join

6 Months and older, any sex, with Malaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the current study, three experimental approaches aiming at reducing malaria transmission will be tested. The study will cover two transmission season (2019 and 2020) and the interventions will vary by season. More specifically, in the 2019 transmission season (June-December) (Year 1), community case management of malaria (CCM) will be implemented in all eight villages as improved standard of care; in the 2020 transmission season (Year 2), the eight study villages will be divided into 4 study arms. CCM will continue in all villages; two villages will continue with CCM only (Arm 1, control); the three other pairs of villages will receive active fever screening and treatment (Arm 2); monthly mass screening and treatment (MSAT) (Arm 3); and mass drug administration (MDA) during the last 3 months of the dry season (April-June) (Arm 4). For MDA, the whole population (except for those not fulfilling the entry criteria) will be treated with a full course of dihydroartemisinin-piperaquine (DP) (320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet) per manufacturer's guidelines (once daily for 3 days and according to body weight). The MDA treatment will be repeated 3 times at monthly intervals.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Household-level effects of seasonal malaria chemoprevention in the Gambia.
Soremekun S, Conteh B, Nyassi A, Soumare HM, et al · · 2024 · cited 10× · PMID 38778226 · DOI 10.1038/s43856-024-00503-0

Verify or expand the search:

Other recruiting trials for Malaria

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting

Other London School of Hygiene and Tropical Medicine trials

Trials by the same sponsor.

NCT06921213 — Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis · Phase 2 · not yet recruiting
NCT06923592 — Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar · Phase 3 · recruiting
NCT06833736 — A Health App Using Recipes and Education Components to Facilitate Sustainable and Healthier Diets. · NA · completed
NCT06166498 — Parasite Clearance and Protection From Infection (PCPI) in Zambia · Phase 3 · completed
NCT06173206 — Parasite Clearance and Protection From Infection (PCPI) in Cameroon · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04053907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by London School of Hygiene and Tropical Medicine
Last refreshed: 31 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04053907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing